secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-12-22T23:59:59+00:00
Accession:  0001437749-25-038478
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Moleculin Biotech Reduces Warrant Exercise Price to $3.90, Boosts Equity Above $10M to Address Nasdaq Delisting
--------------------------------------------------------------------------------

- Entered warrant amendment agreements on Dec 21, 2025 reducing exercise price of Series E, F, G warrants to $3.90 per share.
- Amended Series E and F warrants to delete certain anti-dilution provisions and modify Black Scholes Value definition.
- Received Nasdaq delisting notice on Nov 20, 2025 for non-compliance with $2.5M equity rule; appealed and hearing set for Jan 20, 2026.
- Raised $6.8M from warrant exercise on Dec 9, 2025 and $1.1M from ATM facility; stockholders' equity now exceeds $10.0M.
- Panel hearing for Nasdaq appeal scheduled for January 20, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925038478/0001437749-25-038478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925038478/mbrx20251221_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-038478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer